Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)
Segment Information
Number of reportable segments | segment			2
Total revenue	$ 4,346	$ 9,282	$ 9,509	$ 13,679
Cost of revenue	654	848	1,870	2,698
Research and development	5,924	23,876	22,910	71,738
General and administrative	5,653	7,091	16,217	24,198
Licensing	1,754	7,344	4,070	8,955
Revaluation of contingent consideration	800	1,700	3,800	(600)
Restructuring expense	32		2,899
Loss from operations	(10,471)	(31,577)	(42,257)	(93,310)
Therapeutics Segment
Segment Information
Total revenue	3,701	8,577	7,583	11,210
Contract Research Segment
Segment Information
Total revenue	645	705	1,926	2,469
Operating Segments | Therapeutics Segment
Segment Information
Research and development	6,129	24,110	23,555	72,490
Licensing	1,754	7,344	4,070	8,955
Revaluation of contingent consideration	800	1,700	3,800	(600)
Restructuring expense	32		1,650
Loss from operations	(5,014)	(24,577)	(25,492)	(69,635)
Operating Segments | Contract Research Segment
Segment Information
Total revenue	3,035	4,112	10,122	12,122
Cost of revenue	3,485	4,726	11,346	14,068
General and administrative	905	1,174	3,033	3,490
Restructuring expense			217
Loss from operations	(710)	(1,083)	(2,548)	(2,967)
Corporate and Other
Segment Information
Total revenue	(3,035)	(4,112)	(10,122)	(12,122)
Cost of revenue	(2,831)	(3,878)	(9,476)	(11,370)
Research and development	(205)	(234)	(645)	(752)
General and administrative	4,748	5,917	13,184	20,708
Restructuring expense			1,032
Loss from operations	$ (4,747)	$ (5,917)	$ (14,217)	$ (20,708)